Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNEXA-RS
2022-501353-37-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 39
01
Overview
Phase 3, randomised trial of andexanet alfa in Bleeding (2 arms), sponsored by AstraZeneca. Primary endpoint: Effective intraoperative hemostasis. Started Jan 2024; status: completed.
02
Drugs
andexanet alfa
03
Conditions
Bleeding
Beyond the preview
Go deeper on 2022-501353-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501353-37-00.